anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide a stable and low-cost agent containing an extract of Quercus stenophylla Makino or Quercus myrsinaefolia Blume belonging to Fagaceae as the active component, capable of effectively scavenging superoxides and blendable with a food, a cosmetic, etc. CONSTITUTION:The agent contains an extract of Quercus stenophylla Makino belonging to Fagaceae and/or Quercus myrsinaefolia Blume belonging to Fagaceae as the active component. As the raw material Quercus stenophylla Makino and/or Quercus myrsinaefolia Blume, crudely cut green or dried leaves are preferably used. The extract is obtained recommendably, e.g. by adding water and/or an organic solvent such as ethyl alcohol to the raw material and extracting it with heating at a refluxing temperature. In addition, the agent is blended preferably in an amount of 0.01 to 10wt.% on the extract base based on a food or a cosmetic.
On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
An African-American female in her sixties presented to the hospital with intermittent gum bleeding for the past two years along with severe anemia. This case details the differential and workup that lead to the diagnosis of acquired von Willebrand's syndrome (AvWS). A thorough investigation in the possible etiologies of AvWS revealed that the patient had concomitant chronic lymphocytic lymphoma (CLL) and smoldering multiple myeloma (SMM). Due to the concomitant diagnosis of CLL and SMM, there was a dilemma regarding whether CLL, SMM, or both was driving this patient's AvWS. Decision was made to treat the underlying CLL initially with rituximab and later on at recurrence with obinutuzumab/venetoclax with complete resolution of patient's bleeding and normalization of her factor VIII activity, von Willebrand factor antigen levels, and vWF:ristocetin cofactor levels. We believe this is first case in the literature of a patient with AvWS with concurrent CLL and SMM.
Subjects will be provided with the Lucira COVID-19 Test Kit and collect one (1) nasal swab according to the QRI and test the sample on the Lucira COVID-19 All-In-One Test. HCP will observe subject during this process and document any observations and deviations from the QRI.
The Erchonia HP Scanner (HPS) Laser contains 3 independent diodes mounted in scanner devices and positioned equidistant from each other and titled at a 30 degree angle. Each scanner emits 17 milliwatts (mW), 635 nm of red laser light.
Saline intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
PURPOSE: A volatile fraction from seeds of soybean(Glycine max(L.) Merr.) and a composition comprising the same fraction are provided, which soybean seed volatile fraction is useful for treatment of skin damage, treatment of skin disorder, enhancement of cell regeneration, and promotion of hair growth, and the composition comprising the volatile fraction is useful in medicine composition, cosmetic composition or skin cleansing composition. CONSTITUTION: The volatile fraction from seeds of soybean(Glycine max(L.) Merr.) is prepared by (a) dipping the seeds of soybean(Glycine max(L.) Merr.) in a solution containing 15 wt.% or less of alcohol or water to provide a crude extract of soybean(Glycine max(L.) Merr.) seeds, and (b) volatilizing the crude extract of seeds of soybean(Glycine max(L.) Merr.) at the pressure of 1 atmosphere or less and 110 deg. C, wherein the volatile fraction from seeds of soybean(Glycine max(L.) Merr.) has peaks at the retention time of 2.910, 5.190, 13.190 and 50.815 minutes, analyzed by HPLC using Waters Sphersorb(TM)-ODS2 column; the volatile fraction is collected in liquid phase by cooling the vapor; and the volatile fraction has the alcohol concentration of 5 wt.% or less.
Objective: It is unknown how adults communicate about their experienced listening difficulties with their audiologist. This scoping review aims to explore how adults self-describe the listening difficulties that they experience, and how they communicate about them. Design: A scoping review was conducted between December 2020 and September 2022 to identify published journal articles in which adults described and communicated about their listening difficulties. Study sample: Database searches yielded 10,224 articles initially. After abstract screening and full text review, 55 articles were included for analysis. Results: The listening difficulties that adults described were varied, highlighting the fact that each person has individual experiences. Adults discussed reasons for their listening difficulties, impacts of their listening difficulties, and behavioural responses they adopted to cope with their listening difficulties. Conclusions: This review shows the broad impacts of listening difficulties, and the varied ways in which adults discuss their listening difficulties. There is no available literature reporting how adults communicate about their listening difficulties in a clinical context.
Administration

Adrenalin is a ready to administer product that requires no further dilution prior to infusion. Inspect visually for particulate matter and discoloration prior to administration; solution should be clear and colorless. Do not use if the solution is colored or cloudy, or if it contains particulate matter.

Do not open the aluminum overwrap until time of use. The premixed, ready-to-use infusion bag has a single port for insertion of the infusion set only. This port should not be used to remove content from the bag or add another medication. Once the infusion bag has been connected to the infusion set, it is stable for 24 hours, as long as the bag stays connected to the infusion set. Single dose only. 

Discontinuation 

When discontinuing the infusion, reduce the flow rate gradually. Avoid abrupt withdrawal. Discard unused portion.
NEW MATERIAL:A growth factor having a molecular weight of 18,000 and exhibiting strong affinity to heparin-immobilized sepharose. USE:A vascular endothelial cell growth promotion agent useful for promoting afterialization, mitigating inflammation, promoting keratogenesis and osteogenesis, etc. PREPARATION:A bovine heart is homogenized in a lower alcohol and the precipitate is separated. The precipitate is extracted with an extraction liquid capable of dissolving the objective growth factor (e.g., a liquid composed of 50mM of tris-HCl of pH7, 0.5mM of EDTA, 5mM of benzamidine, 1mM of phenylmethylsulfonyl fluoride, 1mug/ml of leupeptin and 1mug/ml of pepstatin A). The extraction liquid containing extracted growth factor is mixed with a lower alcohol (preferably methanol) and a halogenated hydrocarbon (preferably chloroform) and produced precipitate is separated. The objective growth factor can be extracted from the precipitate with an extraction liquid.
Combined Training consisted of inpatient participants who were treated with 45 minute-conventional training, 5 days a week during 6 weeks. Additionally this group had 45 minute-Robotic-Assisted Gait Training, 2 days a week during 6 weeks.
In this study, we conducted a systematic assessment of the effectsof deoxynivalenol (DON) and T-2 mycotoxins (T-2) on the developmental processes and structural integrity of murine femurs, considering both the isolated and synergistic effects of these toxins. To this end, we divided 72 male mice into nine groups, each subjected to varying dosages of T-2, DON, or their combinations. Over a four-week experimental period, meticulous monitoring was undertaken regarding the mice's body weight, biochemical markers of bone formation and resorption, and the activity of relevant cells. To comprehensively evaluate alterations in bone structure, we employed biomechanical analysis, micro-computed tomography (micro-CT), and transmission electron microscopy.Our findings unveiled a significant revelation: the mice exhibited a dose-dependent decrease in body weight upon exposure to individual mycotoxins, while the combined use of these toxins manifested an atypical antagonistic effect. Furthermore, we observed variations in the levels of calcium, phosphorus, and vitamin D, as well as adjustments in the activities of osteoblasts and osteoclasts, all intricately linked to the dosage and ratio of the toxins. Alterations in biomechanical properties were also noted to correlate with the dosage and combination of toxins. Analyses via micro-CT and transmission electron microscopy further corroborated the substantial impact of toxin dosage and combinations on both cortical and trabecular bone structures.In summation, our research unequivocally demonstrates the dose- and ratio-dependent detrimental effects of DON and T-2 mycotoxins on the growth and structural integrity of murine femurs. These insights accentuate the importance of a profound understanding of the potential risks these toxins pose to bone health, offering pivotal guidance for future toxicological research and public health preventative strategies.
FIELD: medicine. SUBSTANCE: method involves applying official standard Escusanum solution to injured focus before acting with low intensity helium-neon laser. The foci are exposed to defocussed laser beam action with wavelength of 632.9 nm, power density of 1-6 mW/cm 2  all over the injured surface from distance of 25-30 cm. The treatment is carried out as single everyday exposures during 1-5 min. EFFECT: enhanced effectiveness of treatment. 1 tbl
We will include in the study 120 consecutive patients with clinically significant, symptomatic aortic stenosis referred to the Helsinki University Central Hospital for consideration of valve replacement surgery. Patients who can be put on the hospital's normal waiting list for elective angiography (i.e who do not need urgent surgery) and who give their informed consent, will be randomized into two groups to start therapy with candesartan (8 mg/d for 2 weeks, and then 16 mg/d until surgery) or placebo. On average, the overall duration of the drug intervention will be 3 months, i.e., the average time in our institution from referral to surgery. In addition, patients (n=50) undergoing aortic valve replacement surgery due to aortic regurgitation caused by dilation of the aortic root will be included. This population consists of both patients with early sclerotic, i.e., pre-stenotic, changes in their aortic valves (n=30) and of patients without any sclerotic or stenotic changes in their aortic valves (n=20). The group with sclerotic changes in their aortic valves (n=30) will be divided into two groups to receive candesartan (8 mg/d 2 wk, and then 16 mg/d until surgery) (n=15) or placebo (n=15). The removed aortic valves will be examined utilizing real-time PCR, autoradiography, fluorometry, immunohistochemistry, double immunofluorescence, confocal microscopy, and enzyme immunoassays. With these techniques, several markers of inflammation, calcification, fibrosis, and the amount of lipid accumulation and oxidation of LDL in the valves will be examined.
NEW MATERIAL:The compound of formula I. USE:Medicine. A carcinostatic agent which can be administered either orally or parenterally. Dose: 1-24mg/kg daily for adults by oral administration and <=12mg/kg daily for adults by parenteral administration. PREPARATION:The objective compound of formula I can be produced by (1) acetylating aphidicolin of formula II with an acetylation agent such as acetic anhydride-4-dimethylpyridine in pyridine solvent in an inert gas (e.g. N2) atmosphere at room temperature for 2-24hr, (2) dehydrating the resultant compound of formula III (Ac is acetyl) preferably in pyridine solvent in the presence of a dehydration agent such as methanesulfonyl chloride in an inert atmosphere (e.g. N2) at room temperature for 3-6hr to obtain triacetyl-15,16-olefin compound of formula IV and (3) deacetylating the product in KOH-methanol, etc.
The present invention provides aqueous oral formulations containing sertraline, or a pharmaceutically acceptable salt thereof, and a sulfoalkyl ether cyclodextrin. The liquid formulations are pleasant tasting, convenient to use, and chemically and physically stable. The liquid formulations can be administered directly or diluted before administration. Unlike the commercially available ZOLOFT™ formulation, the liquid formulations herein do not precipitate upon dilution with water, fruit juices, sodas or other pharmaceutically acceptable oral liquid carriers. The sulfoalkyl ether cyclodextrin-containing formulation provides significant advantages over the marketed non-aqueous formulation and other cyclodextrin-containing formulations of sertraline. The formulation can be self-preserved against microbial growth. The SAE-CD-containing formulation of sertraline can be provided in liquid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid formulations can be prepared. The formulation is available as a clear solution or a suspension.
BACKGROUND: Biomarkers emerged as powerful adjuncts to conventional clinical care in heart failure (HF). The aim of this study is to evaluate neopterin and NT-pro BNP as diagnostic and prognostic biomarkers in HF.
METHODS: A systematic search was conducted in six electronic databases from inception to July 24th, 2022. Independent reviewers screened the title, abstract and full text then data extraction and critical appraisal of included studies were performed.
RESULTS: A total of eleven studies were included. Neopterin and NT-pro BNP levels were elevated in HF patients as compared to control. Moreover, within HF patients, levels of biomarkers were significantly higher in patients with advanced HF and more severe disease state. Patients who suffered cardiovascular adverse events had high levels of biomarkers. Two studies assessed the effect of treatment on biomarkers levels, showed that levels of neopterin and/or NT-pro BNP decreased with treatment. Studies confirmed the potential of relying on neopterin and NT-pro BNP as diagnostic and prognostic biomarkers in HF in addition to assessing disease severity.
CONCLUSION: Biomarkers levels correlate with disease severity and could be used as diagnostic and prognostic biomarkers in HF. Further research is needed for a definitive conclusion about using these biomarkers to determine the efficacy of therapy.
As matched placebo for this study, sterile normal saline (0.9% sodium chloride for i.v. administration) will be used. It will be given as a bolus injection in the same manner as EPO.
WBH will be completed with a Clearlight Sauna Dome and ancillary equipment to monitor core body temperature. For the verum WBH, participants will be brought to a core body temperature of 101.3°F.
<P>PROBLEM TO BE SOLVED: To provide a sealing device for aseptically storing, in a sealing vessel, a microcapsule enclosing the fine powder of chemical substance, the chemical substance or atomized chemical substance, and by which a cost in device and an installation space are reduced.  <P>SOLUTION: The aqueous solution R of vitamin B1 in a raw material liquid supply tank 21 arranged at the outside of a vacuum freeze drying tower 11 is sprayed from the nozzle 12 of the vacuum freeze drying tower 11 so as to obtain fine frozen objects F. The fine frozen objects F falling in the tower 11 are received by a collection part 13. While the fine frozen objects F are moved to a center short tube part 13p, moisture is sublimated from the fine frozen objects F. The objects F are made to fall from the short tube part 13p, and received by a vibration converyor 14. While being guided to a bottom discharge port 18 by the transfer surface 16 of the spiral transfer part 15 in the conveyor 14, the objects are dried by promoting sublimation. The fine powder P of the vitamin B1 remained after drying is stored in the sealing vessel 55a by way of a first vacuum valve 19, the branch passage 51a of a forked branch part 51, and a second vacuum valve 54a.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 1 x 10 E7 cells (3 ml), Frequency: 0,3 weeks.
FIELD: medicine. SUBSTANCE: composition has Enalapryl dose or its pharmaceutically permissible salt and different dose of Nitrenedipine or its pharmaceutically permissible salt. The composition is administered in single dose as galenic preparation. Method involves a) dissolving Enalapryl maleate in water with organic salt; b) mixing microionized Nitrenedipine with loosening fillers fraction, moistening agents, fragmental diluting agent, gluing agent and plastic diluting agent preliminarily sieved; c) granulating products homogenized at (b) stage with solution produced at (a); d) drying the granulated mass; e) introducing lubricating agent and the rest of the loosening fillers fraction and homogenizing the calibrated granulate; f) pressing the granulate. EFFECT: enhanced effectiveness of treatment; reduced risk of adverse side effects. 10 cl, 3 dwg, 8 tbl
Wheat powdery mildew is an important fungal disease that seriously jeopardizes wheat production, which poses a serious threat to food safety. SJ106 is a high-quality, disease-resistant spring wheat variety; this disease resistance is derived from Wheat-wheatgrass 33. In this study, the powdery mildew resistance genes in SJ106 were located at the end of chromosome 6DS, a new disease resistance locus tentatively named PmSJ106 locus. This interval was composed of a nucleotide-binding leucine-rich repeat (NLR) gene cluster containing 19 NLR genes. Five NLRs were tandem duplicated genes, and one of them (a coiled coil domain-nucleotide binding site-leucine-rich repeat (CC-NBS-LRR; CNL) type gene, TaRGA5-like) expressed 69-836-fold in SJ106 compared with the susceptible control. The genome DNA and cDNA sequences of TaRGA5-like were amplified from SJ106, which contain several nucleotide polymorphisms in LRR regions compared with susceptible individuals and Chinese Spring. Overexpression of TaRGA5-like significantly increased resistance to powdery mildew in susceptible receptor wheat Jinqiang5. However, Virus induced gene silence (VIGS) of TaRGA5-like resulted in only a small decrease of SJ106 in disease resistance, presumably compensated by other NLR duplicated genes. The results suggested that TaRGA5-like confers partial powdery mildew resistance in SJ106. As a member of the PmSJ106 locus, TaRGA5-like functioned together with other NLR duplicated genes to improve wheat resistance to powdery mildew. Wheat variety SJ106 would become a novel and potentially valuable germplasm for powdery mildew resistance.
Discontinue COCs if jaundice develops. Steroid hormones may be poorly metabolized in patients with impaired liver function. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded.

Hepatic adenomas are associated with COC use. An estimate of the attributable risk is 3.3 cases/100,000 COC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage. 

Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (> 8 years) COC users. However, the attributable risk of liver cancers in COC users is less than one case per million users. 

Oral contraceptive-related cholestasis may occur in women with a history of pregnancy-related cholestasis. Women with a history of COC-related cholestasis may have the condition recur with subsequent COC use.
Subjects will consume a low oxalate diet for four days, with blood collections on Days 1 and 4 and 24-hour urine collections on Days 3 and 4. A ten day wash out period will follow, during which participants will consume their normal diet. After the wash out period, subjects will consume a high oxalate diet for four days, with blood and 24-hour urine collections occurring again as described previously.
Bacteria migration at catheter insertion sites presents a serious complication (bacteraemia) with high mortality rates. One strategy to mediate bacteraemia is a physical barrier at the skin-catheter interface. Herein a colorimetric biosensor adhesive (CathoGlu) is designed and evaluated for both colorimetric detection of bacterial infection and application as a bacteria barrier. The design intent combines viscous, hydrophobic bioadhesive with an organic pH indicator (bromothymol blue). Visual observation can then distinguish healthy skin at pH = ∼5 from an infected catheter insertion site at pH = ∼8. The liquid-to-biorubber transition of CathoGlu formulation occurs via a brief exposure to UVA penlight, providing an elastic barrier to the skin flora. Leachates from CathoGlu demonstrate no genotoxic and skin sensitization effect, assessed by OECD-recommended in vitro and in chemico assays. The CathoGlu formulation was found non-inferior against clinically approved 2-octyl-cyanoacrylate (Dermabond™), and adhesive tape (Micropore™) within an in vivo porcine model. CathoGlu skin adhesive provides new opportunities to prevent sepsis in challenging clinical situations.
Study AIM #1 To establish the sensitivity of FDG PET/CT in the diagnosis of acute VTE.

Rationale: We believe that FDG PET/CT can be used to accurately diagnose the presence, extent, and acuity of VTE. It is unrealistic to assume that FDG-PET could or should become the primary imaging modality for evaluating VTE. The cost, compared to Doppler ultrasound, would be prohibitive, and would involve unnecessary radiation of the patient. We intend to establish the value of FDG PET, instead, as an alternative modality for the diagnosis of VTE. Clinical situations where this might prove useful include: 1) the presence of old clot, when the distinction between new and old may be important; 2) evaluation of abdominal, pelvic and thoracic thrombus, where Doppler is difficult-to-impossible because of patient obesity; 3) Complicated anatomy due to the presence of tumor or post-therapeutic changes.

The sensitivity of FDG PET/CT will be established in patients with acute VTE. The accuracy with which sites of abnormal FDG uptake can be related, spatially, to vascular structures will be critical to the success of this study. There is little doubt that this can better be accomplished with PET/CT than with PET alone. PET/CT will be used for all of these studies. Patients with documented acute VTE, will be enrolled. To determine the utility of FDG PET/CT in distinguishing acute from subacute or chronic clot, and to establish the extent of acute clot, the initial whole body PET/CT scan must be performed within 2 weeks of onset of symptoms of DVT, and subsequent limited region PET/CT scans will be performed at 2-3 weeks and at 6 weeks following the initial PET/CT scan. Whenever possible, subjects will be recruited who have unprovoked VTE because the potential benefit to the patient for participating in this study will be greatest for these patients are at a higher risk for harboring an underlying occult malignancy. However, patients with both provoked and unprovoked VTE will be eligible for enrollment under this specific aim.
Patient is stimulated with the same polarity and pulse width as the currently chosen stimulation protocol, but with low frequency (80Hz). Voltage/current will be adjusted to maintain TEED similar to that on the regular stimulation protocol.